Raymond James Financial Inc. Grows Position in GoodRx Holdings, Inc. $GDRX

Key Points

• Raymond James Financial Inc. increased its stake in GoodRx Holdings, Inc. by 54.6%, acquiring a total of 830,950 shares worth approximately $3.66 million.
• GoodRx reported earnings per share of $0.09 and revenue of $203.07 million for the last quarter, both missing analyst estimates, with a projected earnings per share of $0.13 for the current fiscal year.
• As of now, institutional investors and hedge funds own 63.77% of GoodRx, with a mixed outlook from analysts, giving the stock an average rating of "Hold" and a target price of $5.80.

Raymond James Financial Inc. lifted its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 54.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 830,950 shares of the company's stock after acquiring an additional 293,420 shares during the quarter. Raymond James Financial Inc. owned 0.22% of GoodRx worth $3,664,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Northern Trust Corp grew its stake in shares of GoodRx by 13.5% in the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company's stock worth $1,961,000 after acquiring an additional 50,256 shares during the period. XTX Topco Ltd bought a new stake in shares of GoodRx in the first quarter worth approximately $315,000. BNP Paribas Financial Markets bought a new stake in shares of GoodRx in the fourth quarter worth approximately $183,000. Dimensional Fund Advisors LP grew its stake in shares of GoodRx by 22.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock worth $9,264,000 after acquiring an additional 369,553 shares during the period. Finally, Deutsche Bank AG bought a new stake in shares of GoodRx in the fourth quarter worth approximately $137,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Price Performance

NASDAQ:GDRX traded up $0.12 during trading hours on Monday, hitting $4.12. 3,456,462 shares of the stock traded hands, compared to its average volume of 5,878,624. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.75. GoodRx Holdings, Inc. has a 1 year low of $3.31 and a 1 year high of $7.90. The company has a market cap of $1.43 billion, a price-to-earnings ratio of 41.20, a price-to-earnings-growth ratio of 1.74 and a beta of 1.23. The stock has a 50 day moving average price of $4.49 and a 200 day moving average price of $4.45.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The firm had revenue of $203.07 million for the quarter, compared to analysts' expectations of $205.72 million. During the same period in the prior year, the firm earned $0.08 EPS. GoodRx's revenue for the quarter was up 1.2% compared to the same quarter last year. Sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Insiders Place Their Bets

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of GoodRx stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $4.05, for a total transaction of $64,864.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. 4.17% of the stock is owned by corporate insiders.

Analyst Ratings Changes

GDRX has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $6.00 target price on shares of GoodRx in a research report on Monday, August 11th. Raymond James Financial lowered shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research report on Friday, August 8th. Finally, UBS Group cut their target price on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $5.80.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.